WSGR logoWSGR logo
Jennifer Fang
Partner
Corporate
Boston

D617-598-7800

Download vCard
LinkedIn
Open PDF
  • A Recognized Practitioner

    Jennifer was recognized in the 2023 and 2024 editions of Chambers USA, Boston Magazine’s inaugural “Top Lawyers” list, and named a “Go-To Business Lawyer” by Massachusetts Lawyers Weekly.

  • Thought Leadership

    She serves on the General Counsel Advisory Board of the National Venture Capital Association.

  • Focus on Cutting-Edge Life Science Companies

    Jennifer helps a variety of start-ups and pre-IPO companies in the pharmaceutical, biotechnology, medical device and diagnostic industries, combining her legal expertise with her background in Biological Engineering.

Jennifer Fang is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative start-ups grow into successful enterprises by providing counsel to the founders, management teams, and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is experienced in negotiating and executing a variety of corporate transactions, including conversions, spinouts, debt and equity financings, public offerings, PIPEs, mergers and acquisitions, and joint ventures. She also counsels venture capital, growth capital, and strategic investors with respect to their investment transactions and their existing portfolio companies. Her practice focuses on companies that can improve patient lives and healthcare through innovations and advances, including in gene editing, cell therapy, novel therapeutics, synthetic biology, proteomics, diagnostics, bioinformatics, medical devices, and research and manufacturing tools and processes.

Jennifer has been recognized by various publications and organizations for her work in the life sciences industry. Chambers USA notes she is increasing recognized for her work advising emerging life sciences companies on a wide range of corporate matters, including financings, IPOs, and M&A. Jennifer was also honored with the 2022 “Best Under 40” award by the National Asian Pacific American Bar Association (NAPABA), which highlighted her work with growing start-ups to enterprises, and named a “Top Woman of Law” honoree by Massachusetts Lawyers Weekly.

She is also a frequent speaker on corporate and securities topics, such as company formation risks, equity compensation issues, angel and venture financing terms, and founder pitfalls, and currently serves on the General Counsel Advisory Board of the National Venture Capital Association.

Jennifer is co-chair of the firm’s Diversity, Equity, and Inclusion Committee and serves on the investment committee for the firm's affiliated fund, the WS Investment Company. She’s also a member of the firm’s Career Development Committee and the Boston office hiring committee. In her free time, she enjoys mentoring young lawyers, entrepreneurs, and investors in the local community.

Experience

Jennifer Fang is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative start-ups grow into successful enterprises by providing counsel to the founders, management teams, and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is experienced in negotiating and executing a variety of corporate transactions, including conversions, spinouts, debt and equity financings, public offerings, PIPEs, mergers and acquisitions, and joint ventures. She also counsels venture capital, growth capital, and strategic investors with respect to their investment transactions and their existing portfolio companies. Her practice focuses on companies that can improve patient lives and healthcare through innovations and advances, including in gene editing, cell therapy, novel therapeutics, synthetic biology, proteomics, diagnostics, bioinformatics, medical devices, and research and manufacturing tools and processes.

Jennifer has been recognized by various publications and organizations for her work in the life sciences industry. Chambers USA notes she is increasing recognized for her work advising emerging life sciences companies on a wide range of corporate matters, including financings, IPOs, and M&A. Jennifer was also honored with the 2022 “Best Under 40” award by the National Asian Pacific American Bar Association (NAPABA), which highlighted her work with growing start-ups to enterprises, and named a “Top Woman of Law” honoree by Massachusetts Lawyers Weekly.

She is also a frequent speaker on corporate and securities topics, such as company formation risks, equity compensation issues, angel and venture financing terms, and founder pitfalls, and currently serves on the General Counsel Advisory Board of the National Venture Capital Association.

Jennifer is co-chair of the firm’s Diversity, Equity, and Inclusion Committee and serves on the investment committee for the firm's affiliated fund, the WS Investment Company. She’s also a member of the firm’s Career Development Committee and the Boston office hiring committee. In her free time, she enjoys mentoring young lawyers, entrepreneurs, and investors in the local community.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Client Cellino Receives $25 Million ARPA-H Award
On September 10, 2024, Cellino Biotech, Inc. announced that the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has awarded it up to $25 million in funding to develop an ultra-scalable, autonomous, cassette-based advanced biomanufacturing technology for personalized regenerative medicines. Cellino’s NEBULA (NExt-generation Biomanufacturing ULtra-scalable Approach) project is the first project funded by the Scalable Solutions Mission Office under the ARPA-H Open Broad Agency Announcement.

With ARPA-H’s support, Cellino will build a cassette-based biomanufacturing technology capable of scaling the production of personalized regenerative cells (induced pluripotent stem cells) at hospitals nationwide to develop curative medicines for a range of chronic conditions for an increasingly diverse and aging U.S. patient population.

Cellino’s proprietary biomanufacturing technology automates traditionally manual, artisanal processes using an AI-guided, laser-based cell management process to reduce variability and increase the consistency of biomanufactured cell and tissue products. Cellino’s proprietary optical bioprocess will drive a meaningful cost reduction for personalized regenerative medicine biomanufacturing using patient-specific closed cassettes. This effort aligns with ARPA-H’s mission to improve health outcomes for everyone.

Cellino has been a Wilson Sonsini client since 2020, and Wilson Sonsini partner Jen Fang has been advising Cellino on the award and other related matters. For more information on the ARPA-H award, please see Cellino’s news release.
Learn More
Client Highlights
Wilson Sonsini Advises LENZ Therapeutics on $30 Million Private Placement Financing
On July 15, 2024, LENZ Therapeutics (LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, announced that it has entered into a stock purchase agreement with Ridgeback Capital for a $30 million private investment in public equity (PIPE) common stock financing. Wilson Sonsini Goodrich & Rosati advised LENZ on the transaction.
Learn More
View All
Recent Events
Affiliated Programs
2024 Northern New England MedTech Conference & MedTech Collaborative Pitch Competition
On November 12th, Jennifer Fang will be a judge at the annual Live Pitch Competition. The Northern New England MedTech Conference (NNEMTC) is a two-day, in-person experience that brings together the MedTech Collaborative Pitch Competition and Northern New England MedTech Conference in one program.
Learn More
Affiliated Programs
American Cancer Society BrightEdge Entrepreneurs Pitch Event and Converge on Cancer Summit
Wilson Sonsini is proud to sponsor the ACS BrightEdge Entrepreneurs Pitch Event on October 28 and the ACS BrightEdge Converge on Cancer Summit on October 29. Firm partner Jennifer Fang will speak on the panel entitled "Fostering Founders and Entrepreneurs Across the Innovation Impasse" at the summit on Tuesday, October 29th. This is a private, by-invitation-only event.
Learn More
View All
WSGR logo
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.